Skip to main content

Table 1 Impact of SDPR expression and clinic pathologic characteristics in lung adenocarcinoma

From: Prognostic values, ceRNA network, and immune regulation function of SDPR in KRAS-mutant lung cancer

Clinicopathologic variablea HR 95% CI P value
a. SDPR expression associations with overall survival in KRAS-mutant patients (GSE72094) using Cox regression
Expression (low vs high) 0.55 0.31–0.98 0.04
Clinicopathologic variableb HR 95% CI P value
b. Multivariate survival model in KRAS-mutant patients (GSE72094) using Cox regression
SDPR expression (low vs high) 0.53 0.29–0.96 0.04
Gender 0.77 0.41–1.45 0.42
Smoking 0.75 0.37–1.51 0.42
Pathological stage (I vs II–IV) 2.05 1.13–3.70 0.02
c. Impaction of SDPR and clinicopathologic characteristics on overall survival    
   
Clinicopathologic variablea HR 95% CI P value
d. SDPR expression associations with overall survival in lung cancer patients (GSE72094) using Cox regression
SDPR expression (low vs high) 0.44 0.30–0.64 < 0.001
Clinicopathologic variableb HR 95% CI P value
e. Multivariate survival model using Cox regression
SDPR expression (low vs high) 0.47 0.32–0.70 < 0.001
Gender 0.55 0.38–0.82 < 0.001
Smoking 0.78 0.503–1.21 0.26
Pathological stage    < 0.001
 Stage I 0.75 0.16–3.54 0.71
 Stage II 0.25 0.12–0.54 < 0.001
 Stage III 0.48 0.21–1.07 0.07
 Stage IV 0.82 0.37–1.83 0.63
f. Impaction of SDPR and clinicopathologic characteristics on overall survival